Skip to content
Popular Searches
  • # Cancer
  • # Alzheimer's
  • # FDA
  • # DNA
  • # COVID19
  • # CRISPR
  • linkedin
  • facebook
  • instagram
  • twitter
Home BiotechReality – Covering Industry, Business, and Academia

Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.

  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
Trending

Trending

Biofuel and Types – The Energy of Future; explained

5 January 2024

Diagnosis of prostate cancer made advanced by microscopy plus deep learning

12 March 2024

Discovery of bacteria that can destroy Forever Chemicals

20 July 2024

DNA preserved in an amber-like polymer

15 June 2024

Nobel Prize 2023 in Medicine for the scientists behind mRNA COVID-19 vaccines

2 October 2023

“Healthy Skepticism” A New Ad Campaign from Lilly Against Compounded Drugs

2 March 2025

Research: Genes that encode immunity are altered in Alzheimer’s patients blood

12 February 2024

The Two Proteins Involved in Alzheimer’s Disease Have Distinct Effects on Brain Circuitry

7 February 2025

Roche granted FDA breakthrough device designation for VENTANA TROP2, an AI-driven companion diagnostic for non-small cell lung cancer

29 April 2025

Random Amplified Polymorphic DNA (RAPD)

24 August 2023

Brain Tumors Attract Killer T Cells via Molecular Zip Code

7 December 2024

Treatment of lung cancer with a type of allergy medicine – Research

8 December 2023

IMAAVY

Johnson & Johnson’s IMAAVYâ„¢ (nipocalimab-aahu) Receives U.S. FDA Approval, a Novel FcRn Blocker for Generalized Myasthenia Gravis Patients
Healthcare & Pharmaceuticals News Regulatory Approval

Johnson & Johnson’s IMAAVYâ„¢ (nipocalimab-aahu) Receives U.S. FDA Approval, a Novel FcRn Blocker for Generalized Myasthenia Gravis Patients

Ajmal Aseem 1 May 2025

IMAAVY demonstrated a swift and significant decrease in IgG levels, a primary driver of gMG, in key adult and pediatric trials.

Areas Covered

  • Anti-obesity Drugs
  • Applications of Biotechnology
  • Artificial Intelligence
  • Astrobiology
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • Cell Biology
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Life Sciences
  • Machine Learning
  • Medical Devices
  • Mental Health
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Pharmacology
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Staining
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs
Market Analysis
Publish on BiotechReality

  • Amgen Hiring Senior Data Engineer in Hyderabad, India – May 2025
  • Novo Nordisk Hiring Senior Regulatory Affairs Specialist in Seoul, South Korea – May 2025
  • Pfizer Hiring an IT Senior Associate in Chennai, India – April, 2025
  • IQVIA Hiring Clinical Data Specialist in Cochin, India – April 2025
  • Amgen Hiring CRM Engineer (Veeva/Salesforce) in Hyderabad, India – April, 2025
SciRealityPress BiotechReality

A SciRealityPress Associate

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2025
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinuePrivacy policy